While there was no evidence of metformin-induced activation of AMPK in lung tumors, metformin led to decreased levels of circulating insulin and IGF as well as decreased phosphorylation of IGF-IR, AKT and mTOR in tumor tissue. Here, MTOR is linked to neoplasm.